Clinical trials: MCOS
Melanocortin Obesity Syndrome, MCOS
Atomoxetine in Melanocortin Obesity Syndrome
This is a phase 2 randomized placebo-controlled crossover trial to determine the safety and efficacy of atomoxetine for treating obesity caused by loss-of-function variants in the melanocortin-4 receptor (MC4R), the most common…
- Trial name
- MCOS (NCT06899178)
- Testing
- Atomoxetine
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Hemodiafiltration, Chronic Kidney Disease Requiring Chronic Dialysis
Effect of Hemodiafiltration Plus MCOs on Uremic Toxins Removal
Conventional hemodialysis is essential for the treatment of ESRD patients by reducing serum concentration of uremic toxins and correcting fluid overload. Nevertheless, HD removes almost exclusively low-range uremic toxins.
- Trial name
- NCT03938285
- Testing
- Theranova 400 membrane, FxCordiax 120 membrane
- Where
- 2 sites in Mexico
- Volunteers
- 12 people
- Sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez